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sitates evaluation to rule out malignant melanoma. 
Overall, this case adds clinical evidence that TNF-α plays 
a critical role in the differentiation and proliferation of 
melanocytes, inducing the development of melanocytic 
nevi.
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Dear Editor:
Kim et al.1 in their interesting study compared the allergo-
logical data on the oral lichen planus (OLP) with those of 
other published articles regarding the oral lichenoid re-
actions (OLRs). We would underscore that the prognostic 
value of the screening patch test on the clinical behaviour 
of these diseases is significantly different. Regarding to the 
OLRs induced by dental alloy restorations, both the metals 
and particles/ions of the corrosive process are believed 
that could perturb the surface antigens of the basal layer 
keratinocytes in neighboring mucous membranes, result-
ing an autoimmune activation and T-cell-mediated re-
action2. Clinical evidence is supported by fact that ORLs 
can disappear as consequence of replacing of the metal al-
loy—mostly the amalgam fillings—with non-metal materi-
als2. Conversely, in OLP the triggering for the immune-ac-
tivation of the basal layer keratinocytes remains unrecog-
nized and the lesions can rarely achieve a complete heal-
ing2. Medical history and oral examination of a subject 
with OLRs may provide suggestions for the potential sensi-
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tizers, leading to selection of the patch testing allergens. 
Regrettably, a baseline patch testing series it is not suffi-
ciently adequate on the basis of just suspicious allergens 
because, often, unsuspected ones can be useful to de-
termine the allergic sensibilization3. In addition, supple-
mentary patch testing materials that take into account of 
the anamnesis and period of exposure of the subject at po-
tential antigens should be considered. For this reason, 
each patient should get a custom setting of antigenic sub-
stances, in keeping with his history of allergy3. 
Where not provided, the cross-reactivity between metals 
and other substances, can lead to scarce outcomes for 
management of OLRs, giving rise to doubt about the pre-
dictability of patch testing. This investigation remains any-
way useful to identify the type of dental material that can 
be used to substitute the suspect substance(s) that causes 
OLRs. Nevertheless, it seems that the substitution of the 
amalgam fillings can produce meaningful improvements 
in a large part of subjects with OLRs, regardless of patch 
testing results4.
Kim et al.1, have reported clinical relevance in 50% of the 
OLP patients, and improvement in symptoms after re-
moval of the allergen in one case. These findings make 
the screening patch testing advisable also in the OLP pa-
tients, although its prognostic value in the OLP and OLRs 
diseases should be clarified in further study. 
Hopefully, the screening patch testing on a wide amount 
of allergens, in accordance to the history of exposure of 
the patient, should be performed before positioning of 
exogenous biomaterials in oral cavity, in particular in 
ORLs and OLP patients. Accordingly, a positive patch test-
ing outcome (expression of immune activation) is not 
enough reliable to justify the signs and symptoms of clin-
ical illness in the allergic contact dermatitis. Therefore, it 
should not take definitive measures of treatment (replace-
ment of dental materials) on the basis of an only positive 
patch testing outcome.
These aspects can be considered of prominence, espe-
cially in relation to OLRs and OLP which have shown a 
potential tendency to develop a malignant change.
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